In vitro gametogenesis—the conversion of an adult somatic cell into a functional sperm or egg via induced pluripotent stem cells—has been demonstrated in mice. Healthy pups have been born from gametes derived from skin cells. The technique has not yet been replicated reliably in humans, but the trajectory is clear enough that the relevant scientific bodies have started writing position papers on its implications rather than its possibility. Within fifteen to twenty-five years, the practical assumption is that any adult cell could, in principle, be reverse-engineered into a gamete, and that any two adults of any sex or genetic configuration could produce a biological child together.
The collective consequence is not primarily a change in who can become a parent—adoption and gamete donation already allow many configurations—but a change in the genetic substrate of parenthood. Same-sex couples could have a biological child carrying both their genomes. A single person could produce both gametes and have a child genetically derived from one parent alone, what some researchers call a "uniparent." Older adults could produce viable gametes well past natural fertility windows. Cellular material harvested from one person without their knowledge could be used to produce a child genetically theirs without consent. The technology rewrites the relationship between bodies, genomes, and the act of bringing a child into existence.
What also changes is the number of embryos that can be produced per cycle. Current IVF typically yields ten to twenty embryos; in vitro gametogenesis could yield hundreds or thousands. Combined with polygenic screening, this dramatically increases the marginal gain from selection, because the parents are no longer choosing between five candidate genomes but between many more. The selection arithmetic changes from "pick the best of a small pool" to "pick the best of a large pool," and the predicted phenotypic shifts move from negligible to potentially meaningful.
The technology also reorganizes the gamete market. Currently, oocyte donation is constrained by the physical demands on donors, the limited number of donors, and the resulting cost (often twenty thousand dollars per cycle). In vitro gametogenesis would, in principle, make egg production a question of cell culture rather than human ovulation. The economic structure of fertility medicine—currently anchored by the scarcity of donor eggs—would shift toward a structure anchored by the cost of the lab process. Donor anonymity, donor compensation, and the legal status of gametes would each need to be rewritten.
The unity law is implicated because in vitro gametogenesis weakens the link between the body that hosts a person and the gametes that produce the next. It opens forms of family that biology has previously excluded—two genetic fathers, two genetic mothers, single-genome offspring—and it forces the question of what biological parenthood means when biology can be rearranged at the cellular level. The plan law is implicated because the gap between technical capability and regulatory framework is wider than for almost any other reproductive technology currently in development. The revise law is implicated because the framework that needs to be revised does not yet exist coherently anywhere.
Some applications are straightforwardly humane. A young cancer patient losing their fertility to chemotherapy, who currently must choose between aggressive freezing protocols of limited success and accepting future infertility, would gain a much more reliable path to biological children. Couples carrying mitochondrial disorders would gain options. Trans adults who transitioned before considering fertility preservation would have a path back to biological parenthood. These uses align with the existing moral framework of fertility medicine, extending it rather than breaking it.
Other applications break the framework. Producing gametes from cellular material harvested from celebrities, from minors, from deceased persons, or from non-consenting adults is technically straightforward once the basic technology works. Producing a child whose two genetic parents are the same person—the uniparent case—introduces a being with no parallel in human history and unknown developmental consequences. Producing multi-parent children, where four or more adults each contribute genetic material through repeated rounds of in vitro gametogenesis, is technically conceivable and ethically uncharted.
The sixth law's question is whether the framework can be built before the capability is deployed. The historical record is not encouraging. IVF, cloning capability, mitochondrial replacement, germline editing—each has outpaced its regulatory environment, and each has produced its own scandal-and-response cycle. The collective work, if it is to be done seriously, would begin now with the harder applications—non-consensual gamete production, uniparent reproduction, post-mortem gamete derivation—and would draw lines before the lines have to be drawn under pressure.